Joshua Fitch, Senior Editor

Fiona C. Baker, PhD, explains how menopausal sleep disturbance differs from other forms of sleep disruption, citing the role of vasomotor symptoms, hormone changes, and an increased postmenopausal risk of sleep apnea in driving nighttime awakenings.

Originally approved in February 2020, levonorgestrel and ethinyl estradiol has now received FDA approval for an updated labeled strength expected to appear on the market in the fall of 2026.

In part 2 of our discussion with Fiona Baker, PhD, she details how to interpret data from the NIRVANA study, which revealed reductions in wakefulness after sleep onset in the elinzanetant group vs placebo.

Backed by phase 3 data showing an overall success rate of 58.5% versus 60.2% for IV imipenem-cilastatin, tebipenem HBr has been approved by the FDA as the first oral carbapenem antibiotic for the treatment of complicated urinary tract infections in the US.

A post hoc analysis of the phase 2 NIRVANA trial presented at SLEEP 2026 found that elinzanetant reduced WASO versus placebo across in-lab PSG, home-based Sleepiz One+ monitoring, and patient-reported Sleep Diary.

For the first time, ACOG has released its own version of vaccine recommendations, ones that differ from CDC recommendations.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

Aiming to address high maternal mortality rates and close the drug development gap for the 90% of pregnant patients using medications, SMFM's ongoing campaign highlights the vital role of perinatologists in managing high-risk pregnancies.

A cross-sectional analysis of 2024 national survey data published in JAMA Women's Health estimates that 17.9 million US women aged 45 to 64 are overdue for at least 1 recommended cancer screening.

An updated consensus statement from the Society for Maternal-Fetal Medicine confirms that acetaminophen remains the safest first-line treatment for pain and fever during pregnancy.

The FDA has approved Wockhardt’s cefepime and zidebactam, a novel intravenous antibiotic that targets multiple penicillin-binding proteins to treat adults with complicated urinary tract infections.

Nitrofurantoin achieved the highest clinical resolution rates among common UTI antibiotics.

These are the top 5 headlines you might have missed from May 2026.

The Policy Center for Maternal Mental Health's 2026 report cards show a slight national grade improvement to a "C," though a new parental support domain returned an "F" across the United States.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

States with abortion restrictions saw increased expectant management and reliance on less effective treatment regimens for spontaneous abortion.

Cervical cancer screening increased by 2.2 percentage points after program implementation, though 12.6% of eligible individuals received testing kits.

A secondary analysis found that reduced time in target glucose range during labor was associated with increased adverse neonatal outcomes in gestational diabetes.

After adjusting for the mother's mental health, a new meta-analysis found no significant association between common antidepressant use in pregnancy and autism or ADHD in chidlren.

Mifepristone via mail order and telehealth may continue after a Supreme Court ruling kept access in place while a lawsuit progresses.

A randomized clinical trial of 143 childbearing physicians found that a package including smart technology and mentorship significantly limited the rise of postpartum burnout.

“The data show that Tdap vaccination during pregnancy is an effective way to protect infants from a serious disease at a time when they are most at risk," said Rochelle Walensky, MD, MPH.

Daré Bioscience reported that 1789 menstrual cycles of data have been reviewed for Ovaprene, with the DSMB recommending that the trial proceed without modifications.

The vaginal insert will be available starting May 19, 2026.

According to a publication in The Lancet, a multistep process was used to generate a new name to avoid misleading references to ovarian cysts while accurately reflecting the condition's diverse features.

The FDA released final guidance on post-approval pregnancy safety studies to improve how clinicians evaluate the risks of drugs and biologics during pregnancy.

The comprehensive review found no evidence linking HPV vaccination to neurological conditions or adverse pregnancy outcomes across 20 years of data.

Following the presentation of real-world data at HRS 2026, Ridhima Kapoor, MD, details the importance of using continuous 14-day ECG patches to capture arrhythmia burden in pregnant populations.

Take a look back at our coverage (so far) of the 2026 ACOG meeting in Washington, DC

The review of over 120 studies published since 2024 found no credible evidence linking HPV vaccination to serious adverse pregnancy outcomes or other long-term health risks.